

# HBB GENE SEQUENCING ANALYSIS

Patient ID		Gender		Location	
Patient Name		Clinician Name		Sample Collected	
Patient DOB		GA/LMP		Sample Received	
Age		Hospital Name		Report Released	

Test Requested:- HBB Gene Sequencing	Sample Type:- Blood	Sample Quality:- Acceptable
--------------------------------------	---------------------	-----------------------------

## RESULT >>

Sample	Variant Detected	Genotype	Allele Status	Clinical Significance
Archana Roy	HBB: c.79 G>A	HbE	Homozygous	Thalassemia Major
Pintu Das	HBB: c.79 G>A	HbE	Homozygous	Thalassemia Major

## RECOMMENDATION >>

Kindly correlate the results with other clinical findings and Genetic counseling is recommended to understand the inheritance and risk of disease occurrence in future generations.

## INTERPRETATION >>

Variant c.79 G>A of HBB gene is present in Archana Roy and Pintu Das in Homozygous state and the disease indication is Thalassemia Major.

## TECHNOLOGY >>

Sanger sequencing based DNA analysis was performed to identify the mutations in the coding regions and reported mutations in the non-coding regions of  $\beta$  Globin gene (HBB). DNA was isolated from the sample received using a commercial kit that works on the silica- membrane- based DNA purification. Mutation surveyor software V5.1.1 is used for identifying the mutations and the identified sequence alterations are reported in accordance with the Human Genome Variants Society (HGVS) nomenclature and annotated using one or more of the following database/s- ClinVar, OMIM, HGMD and SwissVar.



## UNDERSTANDING THE RESULTS: >>

Mutation Type	Possible Genotype*	Clinical Significance#
$\beta^+$ type	$\beta^+ \beta^+$ $\beta^+ \beta^0$ $\beta^+ \beta$ $\beta \beta$	<b>Thalassemia Intermedia / Major</b> <b>Thalassemia Major</b> <b>Thalassemia Minor</b> <b>Normal</b>
$\beta^0$ type	$\beta^0 \beta^0$ $\beta^+ \beta^0$ $\beta^0 \beta$ $\beta \beta$	<b>Thalassemia Major</b> <b>Thalassemia Major</b> <b>Thalassemia Minor</b> <b>Normal</b>

\* $\beta$  type- Normal functional haemoglobin,  $\beta^+$  type Mutation: Reduced ability to produce  $\beta$  Globin protein with reduced functional capacity for hemoglobin,  $\beta^0$  type mutation: No  $\beta$  Globin will be produced and dysfunctional haemoglobin.

#Thalassemia minor: Patient with one normal copy of the  $\beta$ -Globin gene and may show mild to no symptoms for Thalassemia, Thalassemia major: Patient with both abnormal copies of the  $\beta$  Globin gene and may show acute symptoms for Thalassemia, Thalassemia intermedia- Patient with both abnormal copies of the  $\beta$  Globin gene and may show acute symptoms for Thalassemia at adult stage.

## DISCLAIMER: >>

This test does not distinguish between the alleles present in cis and trans forms. Classification of haemoglobin disorders by genetic data alone may result in incomplete conclusions which may significantly impact overall disorder classification and expected phenotype. The test results does not mean that the risk of carrying or developing Thalassemia/sickle cell anemia is not present and or caused by other known or unknown variations in the genome. Correlation with haemoglobin electrophoresis, red blood cell indices and clinical/family history is required. Limitations: This test will detect greater than 99% of variants in HBB gene excluding large insertions and deletions, which may be a rare phenomenon. Any change in primer binding site can result can interfere with the results and allele dropout cannot be ruled out using this experiment. Benign variants will be provided upon request. The current assay doesn't detect the delta beta inversion deletion mutation or any other mutation on Delta, Gamma and Alpha gene.

As per the PRE-NATAL DIAGNOSTIC TECHNIQUES (REGULATIONS & PREVENTION OF MISUSE) AMENDMENT ACT 2002, sex determination shall not be done for all prenatal samples

## REFERENCE >>

Colah R, Gorakshakar A, Nadkarni A, Phanasgaonkar S, Surve R, Sawant P, Mohanty D, Ghosh K (2009) Regional heterogeneity of bthalassemia mutations in the multi ethnic Indian population. Blood Cells Mol Dis 42:241–246.

Edison ES, Shaji RV, Devi SG, Moses A, Viswabandhya A, Matthews V, George B, Srivastava A, Chandy M (2008) Analysis of b globin mutations in the Indian population: presence of rare and novel mutations and region-wise heterogeneity. ClinGenet 73:331–337.

<http://globin.bx.psu.edu/hbvar/menu.html>

*Divya Kumari*  
 Divya Kumari  
 Research Associate

*Himani Pandey*  
 Dr. Himani Pandey  
 Lab Head - Genomics  
 Post-Doc. Fellowship  
 (Medical Genetics), SGP GIMS



928-909-0609

care@redcliffelabs.com

redcliffelabs.com

All lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

# Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

---

## DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.